Human CDC42 ELISA Kit (A76287)

Name: Human CDC42 ELISA Kit
Brand: Antibodies.com
SKU: A76287
Price: 440.0 GBP
Availability: InStock

1 Citation

Enlarge Image

$625

100% Guarantee

Price Match Guarantee

Shipping Information

Freight/Packing Charges: $40

Dispatched from St. Louis, MO.

Lead Time: 7-11 business days.

Name

Human CDC42 ELISA Kit

Description

Human CDC42 ELISA Kit is a sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of human CDC42 in serum, plasma, tissue homogenates, and other biological fluids.

Assay Type

Sandwich (quantitative)

Principle of Assay

Human CDC42 ELISA Kit (A76287) employs the sandwich enzyme immunoassay technique for the quantitative measurement of human CDC42 in serum, plasma, tissue homogenates, and other biological fluids. An antibody specific for CDC42 has been pre-coated onto a 96-well microtiter plate. The standards and test samples are added into the wells and the CDC42 present in each sample is bound to the wells by the immobilized antibody. Following incubation, the wells are washed and then incubated with Biotinylated Anti-CDC42 Antibody, which binds the captured CDC42 present in each well. Following incubation, unbound biotinylated detection antibody is removed by washing, and an HRP-Streptavidin conjugate is added to the wells and the microtiter plate is incubated. Following incubation and washing, TMB substrate solution is then used to visualize the HRP enzymatic reaction by catalysis to produce a blue-coloured product that changes to yellow after addition of acidic stop solution. The density of yellow is proportional to the amount of CDC42 captured in each well. The concentration of CDC42 can then be calculated by reading the O.D. absorbance at 450nm in a microplate reader and referring to the standard curve.

Platform

Pre-coated Microplate (12 x 8 well strips)

Detection Type

Colorimetric

Instrument

Colorimetric Microplate Reader

Sample Type

Serum, plasma, tissue homogenates, and other biological fluids.

Sensitivity

9.375 pg/ml

Product Range

15.625-1000 pg/ml

Assay Time

4 hours

Reactivity

Human

Recovery

Sample Type	n	Range	Average
Serum	5	88% - 102%	94%
EDTA Plasma	5	85% - 101%	93%
Heparin Plasma	5	89% - 96%	92%

Linearity

Sample Type	n	1:2	1:4	1:8
Serum	5	89-100%	97-105%	90-99%
EDTA Plasma	5	83-97%	86-96%	85-94%
Heparin Plasma	5	85-97%	90-99%	88-99%

Precision

Intra-assay CV: < 8%, Inter-assay CV: < 10%

Storage

Store at +4°C. Do not use past expiration date!

Synonyms

Cell division control protein 42 homolog, G25K GTP-binding protein

Product Note

Information online is representative. Always refer to the Product Manual inside the kit.

Disclaimer

This product is for research use only. It is not intended for diagnostic or therapeutic use.

Kit Components

Item	Quantity	Storage
Pre-Coated 96 Well Microplate	12 x 8 Well Strips	+4°C
Lyopholized Standard	2 Vials	+4°C
Sample Dilution Buffer	20ml	+4°C
Biotinylated Detection Antibody	120µl	+4°C
Antibody Dilution Buffer	10ml	+4°C
HRP-Streptavidin Conjugate	120µl	+4°C
SABC Dilution Buffer	10ml	+4°C
TMB Substrate	10ml	+4°C
Stop Solution	10ml	+4°C
Wash Buffer (25X)	30ml	+4°C
Plate Sealers	5 Adhesive Strips	-
Foil Pouch	1 Zip-Sealed Pouch	-

Required Materials

The following materials are not included in the kit, but are required to run this assay:

Microplate reader capable of measuring absorbance at 450nm ± 10nm.
Squirt bottle, multichannel pipette reservoir, or automated microplate washer.
Graph paper or computer software capable of generating logarithmic functions.
Test tubes and Eppendorf tubes to prepare standards and samples.
Multi- and single-channel pipettes and sterile pipette tips.
Deionized or distilled water.
Absorbent paper towels.
37°C incubator.

Important Notes

Sample concentrations should be estimated before being used in the assay and a proper dilution factor should be selected to make the diluted target protein concentration fall in the optimal detection range of this kit.
Sample matrix components will interfere with the test results. All samples must be diluted at least 1:2 with Sample Dilution Buffer.
Hemolysis can greatly impact the validity of test results. Take care to minimize hemolysis.
This ELISA kit is intended for the analysis of biological samples and has not been validated for purified/recombinant proteins, industrial, or commercial materials. Performance with such samples cannot be guaranteed, as differences in expression, sequence, tags, folding, post-translational modifications, purity, activity, or buffer composition may affect assay results. For further guidance, please contact our technical support team.

Bring all reagents and samples to room temperature before use.

We recommend that all standards and samples be assayed in duplicate.

Step 1

Prepare all reagents, samples, and working standards as directed in the previous sections.

Step 2

Determine the number of microplate strips required for the assay and insert them into the plate frame. Unused strips should be stored in the foil pouch at +4°C.

Step 3

Add 100μl of standard solutions to the standard wells. Note: A plate layout is provided to record standards and samples assayed.

Step 4

Add 100μl of samples to the sample wells. Note: All samples must be properly diluted in order to produce sample values within the dynamic range of the assay. All samples must be diluted at least 1:2 with Sample Dilution Buffer.

Step 5

Cover with an adhesive plate sealer provided and incubate at 37°C for 90 minutes.

Step 6

Remove the plate sealer, aspirate the liquid from the plate, and wash the plate two times with Wash Buffer. Soak wells with 350μl of Wash Buffer for 1-2 minutes each time. Note: Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Blot the plate onto paper towels or other absorbent material. Do not let the wells dry completely at any time!

Step 7

Add 100μl of Biotinylated Detection Antibody working solution to each well.

Step 8

Cover with a new adhesive plate sealer and incubate at 37°C for 60 minutes.

Step 9

Remove the plate sealer, aspirate the liquid from the plate, and wash the plate three times with Wash Buffer. Soak wells with 350μl of Wash Buffer for 1-2 minutes each time.

Step 10

Add 100μl of HRP-Streptavidin Conjugate (SABC) working solution to each well.

Step 11

Cover with a new adhesive plate sealer and incubate at 37°C for 60 minutes.

Step 12

Remove the plate sealer, aspirate the liquid from the plate, and wash the plate five times with Wash Buffer. Soak wells with 350μl of Wash Buffer for 1-2 minutes each time.

Step 13

Add 90μl of TMB Substrate to each well. Cover with a new adhesive plate sealer and incubate at 37°C in the dark for 10-20 minutes. Note: This incubation time is for reference only, the optimal reaction time should be determined by the end-user and can be shortened or extended according to the actual color change. The reaction may be terminated when a gradient is apparent in the standard wells. Do not exceed 30 minutes!

Step 14

Add 50μl of Stop Solution to each well. The color in the wells should change from blue to yellow immediately. Note: If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.

Step 15

Determine the optical density (O.D. value) of each well immediately using a microplate reader set to 450 nm.

Scientific Validation DataValidation Data (1)

Enlarge Image

Standard Curve - Human CDC42 ELISA Kit (A76287)

Representative standard curve for Human CDC42 ELISA Kit (A76287).

Product Citations (1)

View Publication

Interferon gamma applied ex vivo restores function to neutrophils from critically ill patients

This publication cites Human CDC42 ELISA Kit (A76287).

Article Abstract

Introduction: Critically ill patients commonly develop acquired neutrophil dysfunction, which increases susceptibility to intensive care unit-acquired infection (ICU-AI). This study aimed to assess whether interferon gamma (IFN-?) can restore function in dysfunctional neutrophils from critically ill patients and to uncover potential underlying mechanisms.

Methods: This was an observational cohort study. Neutrophils were isolated from whole blood donated by critically ill patients (n=31) in four separate teaching hospital intensive care units (ICUs). Neutrophils were subsequently treated with recombinant human IFN-? or vehicle for 1 hour following either Fc gamma receptor (Fc?R) blockade, selective inhibition of the gamma isoform of phosphoinositide 3-kinase (PI3K-?) or vehicle control for 30 min. Neutrophil phagocytosis, bacterial killing, superoxide generation, phagocytic receptor expression and small Rho GTPase activity were assessed. Neutrophil dysfunction was defined as <50% of cells ingesting 2 or more zymosan particles in a phagocytosis assay.

Results: IFN-? significantly improved phagocytosis (control 36.5%, IFN-? 56.0%), bacterial killing (control 31.6%, IFN-? 82.1%) and superoxide generation (2.8-fold increase relative to control) in dysfunctional neutrophils. IFN-? also increased the activity of the small GTPases, Rac and Cdc42 (2.4-fold and 1.5-fold increase relative to control, respectively) in dysfunctional neutrophils. Selective inhibition of PI3K-? prevented the IFN-?-mediated improvement of phagocytosis (IFN-? 62.5%, with inhibitor 27.9%), bacterial killing (IFN-? 82.1%, with inhibitor 30.5%) and superoxide generation (IFN-? 2.8-fold change relative to control, 0.7 with inhibitor). The IFN-?-mediated improvement of bacterial killing in dysfunctional neutrophils was also prevented by Fc?R blockade (IFN-? 82.1%, Fc?R inhibition 28.7%).

Conclusions: In critically ill patients with known acquired neutrophil dysfunction, ex vivo application of IFN-? consistently improved a range of neutrophil effector functions.

View Publication

Publishing research using Human CDC42 ELISA Kit (A76287)? Please let us know so that we can list the citation on this page.